Hans Bishop, Grail CEO (Victor J. Blue/Bloomberg via Getty Images
March 30, 2021 05:20 PM EDTUpdated April 2, 12:11 PM
Deals
FDA+

Look­ing to crack down on big bio­phar­ma M&A deals, FTC sues to block Il­lu­mi­na's $8B Grail ac­qui­si­tion

Jason Mast

Editor

For the sec­ond time in as many years, the FTC is try­ing to block Il­lu­mi­na from mak­ing a mul­ti-bil­lion dol­lar ac­qui­si­tion.

The fed­er­al agency filed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times